CD4 and Autoimmunity: Since both LiNKTR1 and CD4 + TR1 cells use IL-10 and IL-21 and similar mechanisms to suppress autoimmunity, and since both cell types have intrinsic disease-suppressing properties, our data suggest the possibility that simultaneous treatment with both compounds might have superior (additive or synergistic) therapeutic effects.